- Cardiol Therapeutics (CRDL) is pleased to announce the appointment of Michael J. Willner to its Board of Directors
- Michael J. Willner has practiced as both an Attorney and a Certified Public Accountant
- He has practiced real estate and corporate law with New York City-based Milbank, Tweed, Hadley & McCloy
- Mr. Willner has been an advisor to Cardiol since December 2019
- Cardiol Therapeutics is a clinical-stage biotechnology company focused on anti-inflammatory therapies for the treatment of cardiovascular disease
- Cardiol Therapeutics Inc. (CRDL) opened trading at C$4.76 per share
Cardiol Therapeutics (CRDL) is pleased to announce the appointment of Michael J. Willner, Esq. to its Board of Directors, effective immediately.
Michael J. Willner has practiced as both an Attorney and a Certified Public Accountant. He graduated from Emory University Law School as a member of the Emory Law Review. He has practiced real estate and corporate law with New York City-based Milbank, Tweed, Hadley & McCloy, one of the nation’s most prominent international law firms. Prior to his legal career, Mr. Willner was employed by the former Arthur Andersen & Company, a national accounting firm, where he practiced in Arthur Andersen’s tax department.
Mr. Willner has been a very active and successful opportunistic investor for over forty years and is the founder of Willner Capital, Inc., an investment company specializing in public and private equities. Over the past ten years, Willner Capital has made significant investments in both the biotechnology and pharmaceutical cannabinoid industries, focusing primarily on clinical-stage companies that seek to address significant unmet medical needs. Mr. Willner has served as a moderator and participant on numerous panel discussions and advisory boards regarding his investments in the pharmaceutical side of the cannabinoid industry.
“I am pleased to welcome Michael Willner to Cardiol’s Board of Directors,” said Dr. Guillermo Torre-Amione, Chairman of Cardiol Therapeutics.
“An advisor to the company since December 2019, Michael has supported the company’s corporate development and capital markets initiatives which have resulted in significant progress with respect to the development of our lead drug candidate and have placed Cardiol in a strong financial position to complement our recent successful up-listing to NASDAQ. We are delighted that Michael has agreed to join the Board and provide his insights and experience as we advance the clinical development of important therapies aimed at improving the standard of care for people with inflammatory heart disease.”
Deborah Brown has stepped down from the Board of Directors to allow her to focus on her new responsibilities in the global pharma venture which acquired Accelera Canada, the consulting firm of which she was a co-founder and Managing Partner. Cardiol would like to take this opportunity to thank Deborah for her contributions to the Company as a founding director and wish her the very best with her latest endeavour.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on anti-inflammatory therapies for the treatment of cardiovascular disease.
Cardiol Therapeutics Inc. (CRDL) opened trading at C$4.76 per share.
